Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AZD1152 versus low-dose cytarabine in older patients with newly diagnosed acute myeloid leukemia unfit for intensive induction
2009-010114-30Phase 2Terminated
- Sponsor
- AstraZeneca
- Start
- Apr 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of barasertib in acute myeloid leukemia (AML) (3 arms), sponsored by AstraZeneca. Primary endpoint: Overall Complete Response Rate. Started Apr 2009; status: terminated.
02
Drugs
barasertib
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on 2009-010114-30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-010114-30.